Recommendations for using TNF伪 antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health

详细信息    查看全文

• 作者：Vincent Go毛b ; Marc Ardizzone ; Laurent Arnaud ; J茅r么me Avouac ; Athan Baillet ; Alex ; re Belot ; B茅atrice Bouvard ; Pascal Coquerelle ; Sabrina Dadoun ; Alain Diguet ; David Launay ; Danielle Lebouc ; Pierre Loulergue ; Sophie Mahy ; Pascal Mestat ; Ga毛l Mouterde ; Benjamin Terrier ; Coralie Varoquier ; Mathieu Verdet ; Xavier Pu茅chal ; et al.
• 关键词：TNF伪 antagonist ; Etanercept ; Adalimumab ; Infliximab ; Golimumab ; Certolizumab ; Cancer ; Infection ; Vaccination ; Pregnancy ; Older patients ; Surgery ; Vasculitis ; Paradoxical adverse events ; Recommendations ; French National Authority for Health (HAS)
• 刊名：Joint Bone Spine
• 出版年：December, 2013
• 年：2013
• 卷：80
• 期：6
• 页码：574-581
• 全文大小：367 K

文摘

The use of TNF伪 antagonists must follow specific guidelines to ensure optimal effectiveness and safety. The French Society for Rheumatology (SFR) and Task Force on Inflammatory Joint Diseases (CRI), in partnership with several French learned societies, asked the French National Authority for Health (HAS) to develop and endorse good practice guidelines for the prescription and monitoring of TNF伪 antagonist therapy by physicians belonging to various specialties. These guidelines were developed, then, validated by two multidisciplinary panels of experts based on an exhaustive review of the recent literature and in compliance with the methodological rules set forth by the HAS. They pertain to the initial prescription of TNF伪 antagonists and to a variety of clinical situations that can arise during the follow-up of patients receiving TNF伪 antagonists (infections, malignancies, pregnancy, vaccination, paradoxical adverse events, surgery, use in older patients, and vasculitides).